Back to Browse Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 4

Pegylated interferon 2a and 2b in combination with ribavirin for the treatment of chronic hepatitis C in HIV infected patients

Authors Ravinder Dhillon, Simona Rossi, Steven K Herrine

Published 8 August 2008 Volume 2008:4(4) Pages 789—796

DOI http://dx.doi.org/10.2147/TCRM.S2093

Ravinder Dhillon, Simona Rossi, Steven K Herrine

Department of Medicine, Division of Gastroenterology and Hepatology, Thomas Jefferson University, Philadelphia, PA, USA

Abstract: Coinfection with hepatitis C virus (HCV) and HIV is an increasingly recognized clinical dilemma, particularly since the advent of highly active antiretroviral therapy. Several studies of this population have demonstrated both more rapid progression of liver disease and poorer overall prognosis compared to HCV monoinfected patients. Consensus guidelines, based primarily on the results of 4 major randomized trials, recommend treatment with peginterferon and ribavirin for 48 weeks in coinfected patients. However, this current standard of care is associated with lower response rates to therapy than those seen in monoinfected patients. Important predictors of response include HCV genotype, pretreatment HCV RNA level, and presence of rapid virologic response (RVR) and early virologic response (EVR). Use of weight-based ribavirin dosing appears to be safe and enhances the likelihood of sustained virologic response (SVR). Adverse effects most commonly encountered are anemia and weight loss. Mitochondrial toxicity can occur in the setting of concomitant nucleoside reverse transcriptase inhibitor use, especially didanosine, abacavir, and zidovudine, and these should be discontinued before initiation of ribavirin therapy. Discontinuation of therapy should be considered in patients failing to demonstrate EVR, though ongoing trials are investigating a potential role for maintenance therapy in these patients. Peginterferon combined with weight-based ribavirin is appropriate and safe for treatment of HCV in HIV – HCV coinfected patients. This review summarizes the data supporting these recommendations.

Keywords: hepatitis C, human immunodeficiency virus, peginterferon, ribavirin

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Applying Expectancy Theory to residency training: proposing opportunities to understand resident motivation and enhance residency training

Shweiki E, Martin ND, Beekley AC, Jenoff JS, Koenig GJ, Kaulback KR, Lindenbaum GA, Patel PH, Rosen MM, Weinstein MS, Zubair MH, Cohen MJ

Advances in Medical Education and Practice 2015, 6:339-346

Published Date: 29 April 2015

Delivering hydrophilic and hydrophobic chemotherapeutics simultaneously by magnetic mesoporous silica nanoparticles to inhibit cancer cells

Liu Q, Zhang J, Sun W, Xie QR, Xia W, Gu H

International Journal of Nanomedicine 2012, 7:999-1013

Published Date: 24 February 2012

Impact of heat treatment on size, structure, and bioactivity of elemental selenium nanoparticles

Zhang J, Taylor EW, Wan X, Peng D

International Journal of Nanomedicine 2012, 7:815-825

Published Date: 17 February 2012

Surface decoration by Spirulina polysaccharide enhances the cellular uptake and anticancer efficacy of selenium nanoparticles

Yang F, Tang Q, Zhong X, Bai Y, Chen T, Zhang Y, Li Y, Zheng W

International Journal of Nanomedicine 2012, 7:835-844

Published Date: 17 February 2012

Ocular hypotensive effect and safety of travoprost 0.004%/timolol maleate 0.5% fixed combination after change of treatment regimen from ß-blockers and prostaglandin analogs

Inoue K, Setogawa A, Higa R, Moriyama R, Wakakura M, Tomita G

Clinical Ophthalmology 2012, 6:231-235

Published Date: 10 February 2012

Development of an MRI-visible nonviral vector for siRNA delivery targeting gastric cancer

Chen Y, Wang W, Lian G, Qian C, Wang L, Zeng L, Liao C, Liang B, Huang B, Huang K, Shuai X

International Journal of Nanomedicine 2012, 7:359-368

Published Date: 31 January 2012

Methotrexate-induced cutaneous ulceration in patients with erythrodermic mycosis fungoides

Debra L Breneman, Timothy J Storer, John C Breneman, Diya F Mutasim

Therapeutics and Clinical Risk Management 2008, 4:1135-1141

Published Date: 10 October 2008

Beclomethasone/formoterol fixed combination for the management of asthma: patient considerations

Gabriele Nicolini, Nicola Scichilone, Andrea Bizzi, Alberto Papi, Leonardo M Fabbri

Therapeutics and Clinical Risk Management 2008, 4:855-864

Published Date: 10 October 2008

Concurrent Chagas’ disease and borderline disseminated cutaneous leishmaniasis: The role of amiodarone as an antitrypanosomatidae drug

Alberto E Paniz-Mondolfi, Alexandra M Pérez-Álvarez, Oscar Reyes-Jaimes, Gustavo Socorro, Olga Zerpa, et al

Therapeutics and Clinical Risk Management 2008, 4:659-663

Published Date: 6 June 2008